hotspot -WSS

hotspot

author：entertainment 2025-09-29 02:46:42 - browse：163

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： JPM: CVS says Medicare Advantage patients are impacting profits

entertainment

WSS

The cancer stories no one wants to hear

Florida officials tell state schools to teach AP Psychology 'in its entirety'

3 trends to watch in health tech's hiring outlook for 2024

Videos point to link between seizures and unexplained toddler deaths

H.R. 3 is the wrong path to lower drug costs

Chris Christie meets with Zelenskyy during Ukraine trip

focus

hotspot

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The cancer stories no one wants to hear

Cancer drug shortages should be causing more outrage

JPM: CVS says Medicare Advantage patients are impacting profits

Psychedelics group wrestles with new pharma identity

FDA scientists endorse Pfizer/BioNTech Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

In age of alternative facts, a scholarly course on calling out crap

J&J to buy cancer drug developer Ambrx Biopharma

knowledge

H.R. 3 is the wrong path to lower drug costs

'Null' research findings aren't empty of meaning. Let's publish them

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

FDA scientists endorse Pfizer/BioNTech Covid

White House finalizes ITC's import ban of latest Apple Watches

Feng Zhang, Grail founder join forces on new gene editing startup

explore

entertainment

focus

Wikipedia